Open menu for mobile Close menu for mobile


Recent grants made

Haematology Trials Group Update

LRT approved a grant to fund a Senior Trials Co-Ordinator post within the Haematology Trials Group for 2 years from June 2017. This was to facilitate the publishing and archiving of high quality trials that had been closed to recruitment. This task is a valuable element in ensuring that important data is recorded appropriately, especially where ground-breaking studies had resulted, and can then be made available to the lymphoma community (physicians, funders and patients).

Dr. Heather Long, University of Birmingham

In November 2016, the trustees awarded Dr. Heather Long a grant of £20,000 for her project investigating the immune microenvironment of post-transplant lymphoma in a standardised clinical trial cohort. Due to patient samples being delayed this trial was only started in April 2017, but has since recruited very successfully and good progress is being made. Dr. Long has set up assays and started the analysis of the trial cohort and we look forward to her update in due course.


Dr. Thomas Menter, Imperial College London.

Dr. Menter was awarded £17,700 for his project on post transplantation-associated lymphoproliferative disorders (PTLD). A recent update was provided by Dr. Menter in April 2017 which we share below.

In this study, the aim was to characterise lymphomas arising in patients suffering from PTLD at the genetic levels. As this is a rare disease, the cohort of the University Hospital Basel, Switzerland was joined with the cohort of the Imperial College Healthcare NHS Trust, London in order to have a sufficient number of cases (total number of 50).

The research team investigated a large number of different genes involved both in potential pathways of lymphoma development, as well as genes which are important as indicators for new treatment options beyond standard chemotherapy, and those which have a predictive and prognostic value. For this, they used recently established cutting edge technologies of gene analysis (Next Generation Sequencing, NGS) which allow a both more cost-effective and more comprehensive approach than other techniques.

This important study of this rare type of lymphomas is the first analysing the mutational profile of PTLDs, and has both a therapeutic and a potential diagnostic impact.

Dr Menter says: “The support of the Lymphoma Research Trust helped us to retrieve and work up the patients’ biopsies and perform the genetic analyses. Furthermore, it also helped to cover the publication charges. The scientific publication of our work has been accepted by the British Journal of Haematology.”

Dr Jennifer Vidler, King’s College Hospital.

In July 2014, £7,718.76  was awarded to Dr Vidler who is investigating the gene expression of the Epstein-Barr Virus (EBV) and the host using real-time PCR assays in patients who have had a bone marrow transplant. She provided the following update in Dec 2016;

Our project looked at a selection of Epstein-Barr Virus (EBV) and host genes in the blood of patients who had undergone a bone marrow transplant.  We used real-time polymerase chain reaction to investigate these genes and how their expression might be different in patients who went on to develop post-transplant lymphoproliferative disease (PTLD). Our research provided some interesting results that have led on to further research projects and the findings have been presented at the Clinical Virology Network meeting at the Microbiology Society Annual Meeting 2016.

Core grant to Haematology Trials Group.

In November 2015 the trustees awarded funding to the value of £268,104 to the Haematology Trials Group for three years from 2016 to 2018. This will support the next generation of national and international trials and facilitate the long-term assessment of treatment efficacy and treatment related toxicity. In this way the grant will contribute towards improvement of patient care, with the development and optimisation of therapy resulting in a reduction in morbidity and morality.